ROCHESTER, N.Y., January 5, 2026—Findings from two scientific posters presented by CooperVision at the 2026 Global Specialty Lens Symposium (GSLS) offer new myopia control and presbyopia / multifocal contact lens insights for eye care professionals (ECPs).
"CooperVision continues to advance foundational ocular science and research that clinicians can use with patients in the near term. The science we are sharing during GSLS builds on a body of existing myopia and presbyopia work that has helped evolve how these widespread issues are understood and addressed through contact lens innovation," said Karen Walsh, MCOptom, PGDip, FAAO, FIACLE, FBCLA, Senior Director of Global Professional Affairs for CooperVision.
Lens Preference and Visual Performance of Two Myopia Control Contact Lenses (Chang P, et al)1 evaluated how different zonal designs were perceived by children with myopia ages 8 to 15 years with no contact lens wearing experience (n=26). The non-dispensing, single visit, double masked trial contralaterally fit each child with CooperVision MiSight® 1 day* (M1D) and Johnson & Johnson ACUVUE® Abiliti™ 1-Day (AA1D) lenses. After one hour, distance and near vision visual acuity (VA) were assessed under photopic and mesopic conditions, and lens preference was determined using a five-point Likert scale.
Participants’ VA with MiSight® 1 day was more favorable under both photopic and mesopic lighting, and a significantly higher proportion of children achieved 20/20-2 or better photopic distance vision with MiSight® 1 day (81%) compared to AA1D (38%). Among participants with a lens preference (n=20), vision was the predominant factor (n=13); of that subset, 12 of 13 preferred the vision offered by MiSight® 1 day.
The study was run with the Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, at the University of Waterloo.
Computational Optical Modelling to Represent Visual Quality Through Multifocal Contact Lenses (Marullo R, et al)2 acknowledges that ECPs can be challenged to accurately describe how a presbyopic patient may experience corrected vision. This study put forth a method for visually portraying the change, using a computational model to alter images of a street scene outside a window, a computer screen at 74 cm, and cell phone at 40 cm as seen through a single vision contact lens (SVCL) and a low add center-near multifocal contact lens (MFCL).
The resulting pictorial depictions demonstrated how the MFCL design offered better vision quality for near and intermediate objects with minimum impact on distance quality. The investigators suggest that modeling of this type may offer an easier way for ECPs to communicate and facilitate discussions with patients prior to MFCL fitting, helping create realistic outcome expectations. The investigation was conducted in conjunction with the James C. Wyant College of Optical Sciences at the University of Arizona.
A full schedule of events and presentations for GSLS 2026, which takes place in Las Vegas from January 7-10, 2026, is available at gslsymposium.com.
###
* Indications for use: MiSight® 1 day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
1 Chang P et al. Lens Preference and Visual Performance of Two Myopia Control Contact Lenses. Poster presentation. Global Specialty Lens Symposium (GSLS), Las Vegas, January 2026.
2 Marullo R, et al. Computational Optical Modelling to Represent Visual Quality Through Multifocal Contact Lenses. Poster presentation. Global Specialty Lens Symposium (GSLS), Las Vegas, January 2026.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for CooperVision
mike@mcdougallpr.com or +1.585.545.1815